Overcoming the bottlenecks in financing young biotech companies: Experiences from the Munich Cluster,Used

Overcoming the bottlenecks in financing young biotech companies: Experiences from the Munich Cluster,Used

In Stock
SKU: DADAX3638946940
Brand: Grin Publishing
Condition: New
$90.66
Quantity
Add to wishlist
Add to compare
Sold by Ergodebooks, an authorized reseller.

Processing time: 1-3 days

US Orders Ships in: 3-5 days

International Orders Ships in: 8-12 days

Return Policy: 15-days return on defective items

Payment Option
Payment Methods

Help

If you have any questions, you are always welcome to contact us. We'll get back to you as soon as possible, withing 24 hours on weekdays.

Customer service

All questions about your order, return and delivery must be sent to our customer service team by e-mail at yourstore@yourdomain.com

Sale & Press

If you are interested in selling our products, need more information about our brand or wish to make a collaboration, please contact us at press@yourdomain.com

Diploma Thesis from the year 2007 in the subject Business economics Investment and Finance, grade: 1,3, Technical University of Munich (KfW Stiftungslehrstuhl fr Entrepreneurial Finance), language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seedphase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proofofconcept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle.

⚠️ WARNING (California Proposition 65):

This product may contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.

For more information, please visit www.P65Warnings.ca.gov.

Recently Viewed